Compugen Ltd. announced that a bispecific antibody of AstraZeneca derived from COM902, Compugen's high affinity anti-TIGIT antibody, will advance into clinical development. AstraZeneca plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. COM902 was licensed to AstraZeneca in 2018 exclusively for the development of bispecific and multi-specific antibody products, with AstraZeneca responsible for all research, development, and commercial activities. Compugen retains all other rights to the program with exception to those licensed to AstraZeneca.